Company
Henlez
Early-stage biotech company in the dermatology space
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Founded
- 2019
Claim, correct or request removal
Record updated 28 September 2026
About
Henlez mission is to transform the management of skin conditions by using enzymes.
Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic inflammatory condition characterized by severe pain, malodorous drainage and permanent scarring of the armpits and groin. The company was founded 2019 by former Novozymes A/S scientist and current CEO Jeppe Mouritsen.
Funding snapshot
- Total raised
- $1MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Seed, $1M2022-10-27
Funding rounds
- Seed
- $1M2022-10-27, Announced
Loading relationship preview